Atara Biotherapeutics Inc. (NASDAQ:ATRA)’s traded shares stood at 1.35 million during the last session, with the company’s beta value hitting 1.02. At the close of trading, the stock’s price was $3.08, to imply a decrease of -3.14% or -$0.1 in intraday trading. The ATRA share’s 52-week high remains $10.01, putting it -225.0% down since that peak but still an impressive 13.64% since price per share fell to its 52-week low of $2.66. The company has a valuation of $325.74M, with an average of 1.52 million shares in intraday trading volume over the past 10 days and average of 1.29 million shares over the past 3 months.
Analysts have given a consensus recommendation of an Overweight for Atara Biotherapeutics Inc. (ATRA), translating to a mean rating of 2.70. Of 9 analyst(s) looking at the stock, 2 analyst(s) give ATRA a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.39.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
Atara Biotherapeutics Inc. (NASDAQ:ATRA) trade information
After registering a -3.14% downside in the last session, Atara Biotherapeutics Inc. (ATRA) has traded red over the past five days. The stock hit a weekly high of 3.43 this Wednesday, 03/15/23, dropping -3.14% in its intraday price action. The 5-day price performance for the stock is -6.10%, and -30.63% over 30 days. With these gigs, the year-to-date price performance is -6.10%. Short interest in Atara Biotherapeutics Inc. (NASDAQ:ATRA) saw shorts transact 14.07 million shares and set a 16.16 days time to cover.
Analysts on Wall Street suggest a consensus price target of $20.43, implying an increase of 84.92% to the stock’s current value. The extremes give us $2.00 and $50.00 for target low and target high price respectively. As such, ATRA has been trading -1523.38% off suggested target high and 35.06% from its likely low.
Atara Biotherapeutics Inc. (ATRA) estimates and forecasts
Looking at statistics comparing Atara Biotherapeutics Inc. share performance against respective industry, we note that the company has outperformed competitors. Atara Biotherapeutics Inc. (ATRA) shares are -32.60% down over the last 6 months, with its year-to-date growth rate higher than industry average at 20.51% against 9.90%. Revenue is forecast to grow 55.20% this quarter before falling -450.00% for the next one. The rating firms project that company’s revenue will shrink -34.50% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is $30.68 million. Meanwhile, for the quarter ending Jun 2023, a total of 6 analyst(s) estimate revenue growth to $6.2 million.Earnings reports from the last fiscal year show that sales brought in $7.31 million and $51.58 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 319.50% before dropping -88.00% in the following quarter.
ATRA Dividends
Atara Biotherapeutics Inc. has its next earnings report out between May 03 and May 08. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Atara Biotherapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Atara Biotherapeutics Inc. (NASDAQ:ATRA)’s Major holders
Atara Biotherapeutics Inc. insiders hold 1.58% of total outstanding shares, with institutional holders owning 105.34% of the shares at 107.02% float percentage. In total, 105.34% institutions holds shares in the company, led by Blackrock Inc. As of Dec 30, 2022, the company held over 9.15 million shares (or 9.54% of shares), all amounting to roughly $28.19 million.
The next major institution holding the largest number of shares is Wasatch Advisors Inc with 8.39 million shares, or about 8.75% of shares outstanding. As of the market price on Dec 30, 2022, these shares were worth $25.84 million.
We also have SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Wasatch Small Cap Growth Fund as the top two Mutual Funds with the largest holdings of the Atara Biotherapeutics Inc. (ATRA) shares. Going by data provided on Dec 30, 2022, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF holds roughly 4.81 million shares. This is just over 5.02% of the total shares, with a market valuation of $14.83 million. Data from the same date shows that the other fund manager holds a little less at 2.44 million, or 2.55% of the shares, all valued at about 7.52 million.
